Copyright Reports & Markets. All rights reserved.

Global Uterine Fibroids Drug Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Uterine Fibroids Drug Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Oral
      • 1.4.3 Injection
      • 1.4.4 Other
    • 1.5 Market by Application
      • 1.5.1 Global Uterine Fibroids Drug Market Share by Application (2019-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Homecare
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Uterine Fibroids Drug Market Size
    • 2.2 Uterine Fibroids Drug Growth Trends by Regions
      • 2.2.1 Uterine Fibroids Drug Market Size by Regions (2019-2025)
      • 2.2.2 Uterine Fibroids Drug Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Uterine Fibroids Drug Market Size by by Players
      • 3.1.1 Global Uterine Fibroids Drug Revenue by by Players (2014-2019)
      • 3.1.2 Global Uterine Fibroids Drug Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Uterine Fibroids Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Uterine Fibroids Drug Key Players Head office and Area Served
    • 3.3 Key Players Uterine Fibroids Drug Product/Solution/Service
    • 3.4 Date of Enter into Uterine Fibroids Drug Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Uterine Fibroids Drug Market Size by Type (2014-2019)
    • 4.2 Global Uterine Fibroids Drug Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Uterine Fibroids Drug Market Size (2014-2019)
    • 5.2 Uterine Fibroids Drug Key Players in North America
    • 5.3 North America Uterine Fibroids Drug Market Size by Type
    • 5.4 North America Uterine Fibroids Drug Market Size by Application

    6 Europe

    • 6.1 Europe Uterine Fibroids Drug Market Size (2014-2019)
    • 6.2 Uterine Fibroids Drug Key Players in Europe
    • 6.3 Europe Uterine Fibroids Drug Market Size by Type
    • 6.4 Europe Uterine Fibroids Drug Market Size by Application

    7 China

    • 7.1 China Uterine Fibroids Drug Market Size (2014-2019)
    • 7.2 Uterine Fibroids Drug Key Players in China
    • 7.3 China Uterine Fibroids Drug Market Size by Type
    • 7.4 China Uterine Fibroids Drug Market Size by Application

    8 Japan

    • 8.1 Japan Uterine Fibroids Drug Market Size (2014-2019)
    • 8.2 Uterine Fibroids Drug Key Players in Japan
    • 8.3 Japan Uterine Fibroids Drug Market Size by Type
    • 8.4 Japan Uterine Fibroids Drug Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Uterine Fibroids Drug Market Size (2014-2019)
    • 9.2 Uterine Fibroids Drug Key Players in Southeast Asia
    • 9.3 Southeast Asia Uterine Fibroids Drug Market Size by Type
    • 9.4 Southeast Asia Uterine Fibroids Drug Market Size by Application

    10 India

    • 10.1 India Uterine Fibroids Drug Market Size (2014-2019)
    • 10.2 Uterine Fibroids Drug Key Players in India
    • 10.3 India Uterine Fibroids Drug Market Size by Type
    • 10.4 India Uterine Fibroids Drug Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Uterine Fibroids Drug Market Size (2014-2019)
    • 11.2 Uterine Fibroids Drug Key Players in Central & South America
    • 11.3 Central & South America Uterine Fibroids Drug Market Size by Type
    • 11.4 Central & South America Uterine Fibroids Drug Market Size by Application

    12 International Players Profiles

    • 12.1 GSK
      • 12.1.1 GSK Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Uterine Fibroids Drug Introduction
      • 12.1.4 GSK Revenue in Uterine Fibroids Drug Business (2014-2019))
      • 12.1.5 GSK Recent Development
    • 12.2 Roche
      • 12.2.1 Roche Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Uterine Fibroids Drug Introduction
      • 12.2.4 Roche Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.2.5 Roche Recent Development
    • 12.3 Pfizer
      • 12.3.1 Pfizer Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Uterine Fibroids Drug Introduction
      • 12.3.4 Pfizer Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.3.5 Pfizer Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Uterine Fibroids Drug Introduction
      • 12.4.4 Novartis Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Merck
      • 12.5.1 Merck Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Uterine Fibroids Drug Introduction
      • 12.5.4 Merck Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.5.5 Merck Recent Development
    • 12.6 Bristol-Myers
      • 12.6.1 Bristol-Myers Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Uterine Fibroids Drug Introduction
      • 12.6.4 Bristol-Myers Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.6.5 Bristol-Myers Recent Development
    • 12.7 Sanofi
      • 12.7.1 Sanofi Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Uterine Fibroids Drug Introduction
      • 12.7.4 Sanofi Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.7.5 Sanofi Recent Development
    • 12.8 Teva Pharmaceutical Industries
      • 12.8.1 Teva Pharmaceutical Industries Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Uterine Fibroids Drug Introduction
      • 12.8.4 Teva Pharmaceutical Industries Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.8.5 Teva Pharmaceutical Industries Recent Development
    • 12.9 Amgen
      • 12.9.1 Amgen Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Uterine Fibroids Drug Introduction
      • 12.9.4 Amgen Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.9.5 Amgen Recent Development
    • 12.10 Sun Pharmaceutical Industries
      • 12.10.1 Sun Pharmaceutical Industries Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Uterine Fibroids Drug Introduction
      • 12.10.4 Sun Pharmaceutical Industries Revenue in Uterine Fibroids Drug Business (2014-2019)
      • 12.10.5 Sun Pharmaceutical Industries Recent Development
    • 12.11 Bayer
    • 12.12 Endo Pharmaceuticals
    • 12.13 Allergan

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Uterine Fibroids Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Uterine Fibroids Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      GSK
      Roche
      Pfizer
      Novartis
      Merck
      Bristol-Myers
      Sanofi
      Teva Pharmaceutical Industries
      Amgen
      Sun Pharmaceutical Industries
      Bayer
      Endo Pharmaceuticals
      Allergan

      Market segment by Type, the product can be split into
      Oral
      Injection
      Other

      Market segment by Application, split into
      Hospital
      Clinic
      Homecare
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Uterine Fibroids Drug status, future forecast, growth opportunity, key market and key players.
      To present the Uterine Fibroids Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Uterine Fibroids Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now